Rafferty Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Rafferty Asset Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-220,661	Closed	-$2.17M	–	1115
2023 Q1	$2.17M	Sell	220,661 -26,265	-11%	-$448K	0.01%	593
2022 Q4	$4.62M	Buy	246,926 +49,994	+25%	+$1.13M	0.04%	384
2022 Q3	$4.08M	Buy	196,932 +24,282	+14%	+$622K	0.04%	369
2022 Q2	$3.58M	Buy	172,650 +7,665	+5%	+$216K	0.03%	352
2022 Q1	$7.11M	Buy	164,985 +62,312	+61%	+$2.81M	0.04%	266
2021 Q4	$6.15M	Buy	102,673 +40,285	+65%	+$3.23M	0.03%	291
2021 Q3	$5.36M	Buy	62,388 +7,059	+13%	+$708K	0.04%	295
2021 Q2	$6.16M	Sell	55,329 -2,278	-4%	-$219K	0.04%	270
2021 Q1	$6.42M	Buy	57,607 +46,084	+400%	+$6.06M	0.04%	239
2020 Q4	$1.22M	Sell	11,523 -4,881	-30%	-$650K	0.01%	466
2020 Q3	$2.28M	Buy	16,404 +10,292	+168%	+$2.15M	0.03%	374
2020 Q2	$1.98M	Buy	+6,112	New	+$981K	0.03%	356
2019 Q2	–	Sell	-15,713	Closed	-$703K	–	829
2019 Q1	$703K	Buy	+15,713	New	+$792K	0.01%	608

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management's INO Position: Q2 2023 in Review

Rafferty Asset Management sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 220,661 shares — an estimated $2.17M sold.

Rafferty Asset Management first reported a position in INO in Q1 2019 and held it in 13 quarters. The position peaked at $7.11M in Q1 2022. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Rafferty Asset Management reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 220,661 Inovio Pharmaceuticals shares in Q2 2023, an estimated $2.17M.
Rafferty Asset Management first reported a position in Inovio Pharmaceuticals in Q1 2019 and held it in 13 quarters.
Rafferty Asset Management's Inovio Pharmaceuticals position peaked at $7.11M in Q1 2022.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.